SillaJen

신라젠 · 215600

Industrials Commercial Services · KOSDAQ

Small-cap

Market cap US$277.6M (₩383.1B)

Overview

SillaJen is a South Korean biotech company, listed on KOSDAQ, that develops experimental cancer treatments, including engineered viruses designed to infect and destroy tumour cells while stimulating the body's own immune system, and small-molecule drugs that disrupt cancer-cell division.

It also has a pharmaceutical division that develops and supplies generic and improved versions of injectable prescription medicines not previously available in Korea. The company runs two distinct business lines: an oncology drug-development programme and a commercial pharmaceutical operation.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$6.7M

▲ +134.9% YoY

Operating profit · FY2025

−US$18.5M

Loss narrowed

Net income · FY2025

−US$17.5M

Loss narrowed

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$2.9M(₩3.9B)	US$2.8M(₩3.9B)	US$6.7M(₩9.2B)
Operating profit	−US$15.5M(−₩21.3B)	−US$19.4M(−₩26.8B)	−US$18.5M(−₩25.6B)
Net income	−US$14.8M(−₩20.4B)	−US$19.2M(−₩26.5B)	−US$17.5M(−₩24.2B)

Revenue

FY2023US$2.9M
FY2024US$2.8M
FY2025US$6.7M

Operating profit

FY2023−US$15.5M
FY2024−US$19.4M
FY2025−US$18.5M

Net income

FY2023−US$14.8M
FY2024−US$19.2M
FY2025−US$17.5M

Key ratios (FY2025)

ROE

-22.0%

Debt/Eq

6.1%

Op. margin

-277.4%

Net margin

-262.2%

Rev. YoY

▲ +134.9%

Price charts coming soon

Interactive price history isn't here yet. Would you use it?